The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL).
 
Adam J Olszewski
Consulting or Advisory Role - Blue Cross and Blue Shield of Rhode Island; Genmab; Schrodinger; TG Therapeutics
Research Funding - Adaptive Biotechnologies; Celldex (Inst); Genentech/Roche (Inst); Genmab (Inst); Precision Biosciences (Inst); Spectrum Pharmaceuticals (Inst); TG Therapeutics (Inst)
 
Scott F. Huntington
Honoraria - AstraZeneca; Pharmacyclics; Seagen
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Arvinas; AstraZeneca; Bayer; BeiGene; Epizyme; Flatiron Health; Genentech; Janssen; Merck; Novartis; SeaGen; TG Therapeutics; Tyme Inc.
Research Funding - Agios; Celgene; Debiopharm Group; DTRM; TG Therapeutics
Travel, Accommodations, Expenses - Bayer; Celgene; Genentech; Pharmacyclics
 
Thomas Ollila
No Relationships to Disclose
 
Ari Pelcovits
No Relationships to Disclose
 
Jessica B. McMahon
No Relationships to Disclose
 
Inna Yakirevich
No Relationships to Disclose
 
Ashlee Sturtevant
No Relationships to Disclose
 
Anna Chorzalska
No Relationships to Disclose
 
John Morgan
No Relationships to Disclose
 
Patrycja Dubielecka
No Relationships to Disclose